And The UK's First 'Innovation Passport' Goes To... MSD's Rare Disease Drug Belzutifan
Regulator Invites More Applications For New Pathway
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
You may also be interested in...
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
The UK has the potential to fulfill its ambition of being a global superpower in life sciences, but it must not get lost in an echo chamber, says a senior MSD executive.
The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.